This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Dexmedetomidine
  • /
  • The Neuroprotective Effects of Dexmedetomidine Dur...
Clinical trial

The Neuroprotective Effects of Dexmedetomidine During Brain Surgery

Read time: 2 mins
Last updated:5th May 2020
Identifier: NCT02878707
Dexmedetomidine (DEX) is a Alpha-2 specific agonist, is a common ICU sedation medication. In brain tumor resection craniotomy, it is proven to be effective in improving postoperative hypertension and tachycardia, mitigates postoperative nausea and vomiting and relives postoperative pain. In addition, many animal experiments show that DEX inhibits the proapoptosis in the mitochondrial in vivo and therefore avoids neuronal injury. It is also reported to be neuroprotective to isoflurane-induced neurotoxicity and to improve cerebral focal ischemic region (penumbra). However, the neuroprotective effects were never investigated clinically in patients undergoing brain tumor resection surgery.


Category Value
Date last updated at source 2016-08-21
Study type(s) Interventional
Expected enrolment 160
Study start date 2016-08-01
Estimated primary completion date 2018-09-01

View full details